Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.60 |
| ▸ | PPARG | P37231 | 9/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864878 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL2864877 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL20117226 | 0.90 | JAK3 (0.53) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL4502068 | 0.88 | PPARA (0.64) | PPARAPPARGPPARDACECTSK | |
| SCHEMBL4502065 | 0.88 | PPARA (0.64) | PPARAPPARGPPARDACECTSK | |
| SCHEMBL20835599 | 0.88 | PPARA (0.51) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL20835596 | 0.88 | PPARA (0.51) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL28286840 | 0.87 | ALDH1A1 (0.58) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL28286842 | 0.87 | ALDH1A1 (0.58) | PPARAPPARGPPARDACEJAK3 | |
| SCHEMBL7810192 | 0.87 | PPARA (0.58) | PPARAPPARGPPARDACEJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | PPARA 2471/4885PPARG 2287/4885PPARD 1412/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | PPARA 2471/4885PPARG 2287/4885PPARD 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.